SCHEMBL2206852

SCHEMBL2206852

CCOC(=O)C(C)Oc1c(Cl)ccc(P(=O)(c2cc(C(C)(C)C)cc(C(C)(C)C)c2)c2cc(C(C)(C)C)cc(C(C)(C)C)c2)c1-c1c(P(=O)(c2cc(C(C)(C)C)cc(C(C)(C)C)c2)c2cc(C(C)(C)C)cc(C(C)(C)C)c2)ccc(Cl)c1O[C@@H](C)C(=O)OCC

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.35
L3MBTL1 Q9Y468 2/20 0.32
LMNA P02545 1/20 0.32
EPHX2 P34913 2/20 0.31
CYP4F2 P78329 1/20 0.31
CYP4A11 Q02928 1/20 0.31
HMGCR P04035 1/20 0.31
PPOX P50336 1/20 0.31
KDM4E B2RXH2 4/20 0.31
GAA P10253 1/20 0.31
TDP1 Q9NUW8 1/20 0.31
ALDH1A1 P00352 3/20 0.31
HPGD P15428 2/20 0.31
NPSR1 Q6W5P4 2/20 0.31
MAPT P10636 1/20 0.31
MAPK1 P28482 1/20 0.31
MEN1 O00255 1/20 0.30
SMN1; SMN2 Q16637 1/20 0.30
IDH1 O75874 1/20 0.30
TSHR P16473 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2206856 1.00 KMT2A (0.35) KMT2AL3MBTL1LMNAEPHX2CYP4F2
SCHEMBL2213282 0.95 KMT2A (0.32) KMT2A
SCHEMBL2213279 0.95 KMT2A (0.32) KMT2A
SCHEMBL2212060 0.89 MAPT (0.35) KMT2AL3MBTL1LMNAGAAALDH1A1
SCHEMBL2212056 0.89 MAPT (0.35) KMT2AL3MBTL1LMNAGAAALDH1A1
SCHEMBL2208381 0.87 KMT2A (0.33) KMT2AL3MBTL1LMNAEPHX2KDM4E
SCHEMBL2208385 0.87 KMT2A (0.33) KMT2AL3MBTL1LMNAEPHX2KDM4E
SCHEMBL2212762 0.85 MEN1 (0.33) KMT2AL3MBTL1MAPTMEN1
SCHEMBL2212759 0.85 MEN1 (0.33) KMT2AL3MBTL1MAPTMEN1
SCHEMBL2208359 0.84 ALDH1A1 (0.34) KMT2AL3MBTL1LMNAEPHX2CYP4F2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7981827-B2 Chiral phosphanes for use in asymmetric syntheses BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-07-19 US disclosed
US-20100099902-A1 CHIRAL PHOSPHANES FOR USE IN ASYMMETRIC SYNTHESES BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-04-22 US disclosed
US-7625443-B2 Chiral phosphanes for use in asymmetric syntheses BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-12-01 US disclosed
US-20050085377-A1 Chiral phosphanes for use in asymmetric syntheses LIGAND CHEMIE GMBH (DE) 2005-04-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100099902-A1 CHIRAL PHOSPHANES FOR USE IN ASYMMETRIC SYNTHESES PHOSPHO1, AGPS, GGPS1 KMT2A 2926/4885L3MBTL1 3758/4885LMNA 4363/4885
US-20050085377-A1 Chiral phosphanes for use in asymmetric syntheses PHOSPHO1, AGPS, GGPS1 KMT2A 2926/4885L3MBTL1 3758/4885LMNA 4363/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.